CRISPR; clustered regularly interspaced short palindromic repeats

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14]

Introduction

may play role in RNA interference &/or gene editing

Indications

Principle

  • CRISPR-associated system Cas
  • components include
  • result is reduction in gene expression vs reduction in mRNA translation vs reduced production of defective protein
  • CRISPR/Cas9 can be directed to cut DNA in targeted areas, enabling the ability to accurately edit (remove, add, or replace) DNA where it was cut.[14]

Comparative biology

Notes

  • a version of CRISPR that allows selective activation of several specific genes at once is described[3]
  • off-target effects (i.e. genes other than targeted gene) may occur[4]
  • newer technique reduces or eliminates off-target effects[6]

More general terms

More specific terms

Additional terms

References

  1. ↑ 1.0 1.1 Wang T et al. Genetic screens in human cells using the CRISPR-Cas9 system. Science 2014 Jan 3; 343:80 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24336569 <Internet> http://www.sciencemag.org/content/343/6166/80
    Shalem O et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014 Jan 3; 343:84. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24336571 <Internet> http://www.sciencemag.org/content/343/6166/84
  2. ↑ Niu Y et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA- mediated gene targeting in one-cell embryos. Cell 2014 Jan 30; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24486104 <Internet> http://www.cell.com/retrieve/pii/S0092867414000798
    Pennisi E. Transgenic animals. Editing of targeted genes proved possible in monkeys. Science 2014 Jan 31; 343:476 PMID: https://www.ncbi.nlm.nih.gov/pubmed/24482459
  3. ↑ 3.0 3.1 Konermann S et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 2015 Jan 29; 517:583. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25494202
    Cho SW and Chang HY. CRISPR engineering turns on genes. Nature 2015 Jan 29; 517:560 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25631441
  4. ↑ 4.0 4.1 Ran FA et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015 Apr 9; 520:186. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25830891
    Liang P et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 2015 May; 6:363. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25894090
    Baltimore D et al. A prudent path forward for genomic engineering and germline gene modification. Science 2015 Apr; 348:36. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25791083
  5. ↑ 5.0 5.1 Nelson CE, Hakim CH, Ousterout DG et al In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016 Jan 22;351(6271):403-7 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26721684 <Internet> http://science.sciencemag.org/content/351/6271/403
    Long C, Amoasii L, Mireault AA Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016 Jan 22;351(6271):400-3 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26721683 Free PMC Article <Internet> http://science.sciencemag.org/content/351/6271/400
    Tabebordbar M, Zhu K, Cheng JK In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. 2016 Jan 22;351(6271):407-11 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26721686 <Internet> http://science.sciencemag.org/content/351/6271/407
  6. ↑ 6.0 6.1 Kleinstiver BP, Pattanayak V, Prew MS et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome- wide off-target effects. Nature 2016 Jan 28; 529:490 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26735016
  7. ↑ Calos MP The CRISPR Way to Think about Duchene's N Engl J Med 2016; 374:1684-1686. April 28, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27119241 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMcibr1601383
  8. ↑ 8.0 8.1 Ma H, Marti-Gutierrez N, Park SW et al Correction of a pathogenic gene mutation in human embryos. Nature (2017). Published online 02 August 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28783728 <Internet> http://www.nature.com/nature/journal/vaop/ncurrent/full/nature23305.html
  9. ↑ Komaroff AL Gene Editing Using CRISPR. Why the Excitement? JAMA. Published online August 10, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28796848 <Internet> http://jamanetwork.com/journals/jama/fullarticle/2646800
  10. ↑ Cong L, Ran FA, Cox D et al Multiplex genome engineering using CRISPR/Cas systems. Science. 2013 Feb 15;339(6121):819-23. Epub 2013 Jan 3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23287718 Free PMC Article
  11. ↑ Mali P, Yang L, Esvelt KM et al RNA-guided human genome engineering via Cas9. Science. 2013 Feb 15;339(6121):823-6. Epub 2013 Jan 3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23287722 Free PMC Article
  12. ↑ Gootenberg JS, Abudayyeh OO, Lee JW et al Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017 Apr 28;356(6336):438-442. Epub 2017 Apr 13. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28408723 Free PMC Article
  13. ↑ Chen ZH, Yu YP, Zuo ZH et al Targeting genomic rearrangements in tumor cells through Cas9- mediated insertion of a suicide gene. Nat Biotechnol. 2017 Jun;35(6):543-550. Epub 2017 May 1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28459452
  14. ↑ 14.0 14.1 FDA News Release, Dec 8, 2023 FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
Retrieved from "https://aaushi.info/w/index.php?title=A48872&oldid=1230417"